Shandong Weigao Group Medical Polymer Company Limited

SEHK:1066 Aktierapport

Börsvärde: HK$23.8b

Shandong Weigao Group Medical Polymer Framtida tillväxt

Future kriterier kontrolleras 1/6

Shandong Weigao Group Medical Polymer förväntas öka intäkter och intäkter med 9.3% respektive 6.6% per år. EPS förväntas tillväxt med 9.2% per år. Avkastningen på eget kapital förväntas bli 9.1% om 3 år.

Viktig information

9.3%

Tillväxttakt i vinsten

9.2%

Tillväxttakt för EPS

Medical Equipment vinsttillväxt45.6%
Intäkternas tillväxttakt6.6%
Framtida avkastning på eget kapital9.1%
Bevakning av analytiker

Good

Senast uppdaterad21 Feb 2025

Senaste uppdateringarna om framtida tillväxt

Analysts Have Been Trimming Their Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) Price Target After Its Latest Report

Sep 24
Analysts Have Been Trimming Their Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) Price Target After Its Latest Report

Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) Just Reported, And Analysts Assigned A HK$6.74 Price Target

Aug 30
Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) Just Reported, And Analysts Assigned A HK$6.74 Price Target

Analysts Have Lowered Expectations For Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) After Its Latest Results

Mar 28
Analysts Have Lowered Expectations For Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) After Its Latest Results

Recent updates

Shandong Weigao Group Medical Polymer (HKG:1066) Is Reinvesting At Lower Rates Of Return

Feb 07
Shandong Weigao Group Medical Polymer (HKG:1066) Is Reinvesting At Lower Rates Of Return

Is Shandong Weigao Group Medical Polymer (HKG:1066) A Risky Investment?

Nov 26
Is Shandong Weigao Group Medical Polymer (HKG:1066) A Risky Investment?

Be Wary Of Shandong Weigao Group Medical Polymer (HKG:1066) And Its Returns On Capital

Nov 04
Be Wary Of Shandong Weigao Group Medical Polymer (HKG:1066) And Its Returns On Capital

Analysts Have Been Trimming Their Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) Price Target After Its Latest Report

Sep 24
Analysts Have Been Trimming Their Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) Price Target After Its Latest Report

Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) Just Reported, And Analysts Assigned A HK$6.74 Price Target

Aug 30
Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) Just Reported, And Analysts Assigned A HK$6.74 Price Target

Shandong Weigao Group Medical Polymer Company Limited's (HKG:1066) 27% Share Price Plunge Could Signal Some Risk

Jun 25
Shandong Weigao Group Medical Polymer Company Limited's (HKG:1066) 27% Share Price Plunge Could Signal Some Risk

Here's What To Make Of Shandong Weigao Group Medical Polymer's (HKG:1066) Decelerating Rates Of Return

Jun 23
Here's What To Make Of Shandong Weigao Group Medical Polymer's (HKG:1066) Decelerating Rates Of Return

Shandong Weigao Group Medical Polymer's (HKG:1066) Shareholders Will Receive A Bigger Dividend Than Last Year

May 31
Shandong Weigao Group Medical Polymer's (HKG:1066) Shareholders Will Receive A Bigger Dividend Than Last Year

We Think Shandong Weigao Group Medical Polymer Company Limited's (HKG:1066) CEO Compensation Package Needs To Be Put Under A Microscope

May 22
We Think Shandong Weigao Group Medical Polymer Company Limited's (HKG:1066) CEO Compensation Package Needs To Be Put Under A Microscope

Earnings Not Telling The Story For Shandong Weigao Group Medical Polymer Company Limited (HKG:1066)

Apr 23
Earnings Not Telling The Story For Shandong Weigao Group Medical Polymer Company Limited (HKG:1066)

Analysts Have Lowered Expectations For Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) After Its Latest Results

Mar 28
Analysts Have Lowered Expectations For Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) After Its Latest Results

Shandong Weigao Group Medical Polymer Company Limited's (HKG:1066) Shares May Have Run Too Fast Too Soon

Jan 09
Shandong Weigao Group Medical Polymer Company Limited's (HKG:1066) Shares May Have Run Too Fast Too Soon

Returns On Capital Are Showing Encouraging Signs At Shandong Weigao Group Medical Polymer (HKG:1066)

Dec 22
Returns On Capital Are Showing Encouraging Signs At Shandong Weigao Group Medical Polymer (HKG:1066)

Are Investors Undervaluing Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) By 44%?

Nov 10
Are Investors Undervaluing Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) By 44%?

Does Shandong Weigao Group Medical Polymer (HKG:1066) Have A Healthy Balance Sheet?

Oct 05
Does Shandong Weigao Group Medical Polymer (HKG:1066) Have A Healthy Balance Sheet?

Return Trends At Shandong Weigao Group Medical Polymer (HKG:1066) Aren't Appealing

Aug 01
Return Trends At Shandong Weigao Group Medical Polymer (HKG:1066) Aren't Appealing

Is Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) Trading At A 28% Discount?

Jul 19
Is Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) Trading At A 28% Discount?

Shandong Weigao Group Medical Polymer (HKG:1066) Ticks All The Boxes When It Comes To Earnings Growth

Jun 22
Shandong Weigao Group Medical Polymer (HKG:1066) Ticks All The Boxes When It Comes To Earnings Growth

Is Shandong Weigao Group Medical Polymer (HKG:1066) Using Too Much Debt?

Jun 09
Is Shandong Weigao Group Medical Polymer (HKG:1066) Using Too Much Debt?

The Returns At Shandong Weigao Group Medical Polymer (HKG:1066) Aren't Growing

Apr 27
The Returns At Shandong Weigao Group Medical Polymer (HKG:1066) Aren't Growing

Shandong Weigao Group Medical Polymer (HKG:1066) Ticks All The Boxes When It Comes To Earnings Growth

Mar 17
Shandong Weigao Group Medical Polymer (HKG:1066) Ticks All The Boxes When It Comes To Earnings Growth

A Look At The Intrinsic Value Of Shandong Weigao Group Medical Polymer Company Limited (HKG:1066)

Feb 27
A Look At The Intrinsic Value Of Shandong Weigao Group Medical Polymer Company Limited (HKG:1066)

Returns On Capital At Shandong Weigao Group Medical Polymer (HKG:1066) Have Hit The Brakes

Jan 18
Returns On Capital At Shandong Weigao Group Medical Polymer (HKG:1066) Have Hit The Brakes

Does Shandong Weigao Group Medical Polymer (HKG:1066) Have A Healthy Balance Sheet?

Dec 12
Does Shandong Weigao Group Medical Polymer (HKG:1066) Have A Healthy Balance Sheet?

Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) Shares Could Be 21% Below Their Intrinsic Value Estimate

Nov 29
Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) Shares Could Be 21% Below Their Intrinsic Value Estimate

Here's Why We Think Shandong Weigao Group Medical Polymer (HKG:1066) Might Deserve Your Attention Today

Nov 14
Here's Why We Think Shandong Weigao Group Medical Polymer (HKG:1066) Might Deserve Your Attention Today

Shandong Weigao Group Medical Polymer (HKG:1066) Is Paying Out A Larger Dividend Than Last Year

Oct 03
Shandong Weigao Group Medical Polymer (HKG:1066) Is Paying Out A Larger Dividend Than Last Year

The Returns At Shandong Weigao Group Medical Polymer (HKG:1066) Aren't Growing

Sep 21
The Returns At Shandong Weigao Group Medical Polymer (HKG:1066) Aren't Growing

Shandong Weigao Group Medical Polymer (HKG:1066) Could Easily Take On More Debt

Sep 05
Shandong Weigao Group Medical Polymer (HKG:1066) Could Easily Take On More Debt

Shandong Weigao Group Medical Polymer Company Limited's (HKG:1066) Intrinsic Value Is Potentially 27% Above Its Share Price

Aug 23
Shandong Weigao Group Medical Polymer Company Limited's (HKG:1066) Intrinsic Value Is Potentially 27% Above Its Share Price

Here's Why Shandong Weigao Group Medical Polymer (HKG:1066) Has Caught The Eye Of Investors

Aug 08
Here's Why Shandong Weigao Group Medical Polymer (HKG:1066) Has Caught The Eye Of Investors

There's Been No Shortage Of Growth Recently For Shandong Weigao Group Medical Polymer's (HKG:1066) Returns On Capital

Jun 22
There's Been No Shortage Of Growth Recently For Shandong Weigao Group Medical Polymer's (HKG:1066) Returns On Capital

Shandong Weigao Group Medical Polymer (HKG:1066) Will Pay A Smaller Dividend Than Last Year

Jun 08
Shandong Weigao Group Medical Polymer (HKG:1066) Will Pay A Smaller Dividend Than Last Year

An Intrinsic Calculation For Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) Suggests It's 27% Undervalued

May 16
An Intrinsic Calculation For Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) Suggests It's 27% Undervalued

Is Shandong Weigao Group Medical Polymer (HKG:1066) A Risky Investment?

May 03
Is Shandong Weigao Group Medical Polymer (HKG:1066) A Risky Investment?

Shandong Weigao Group Medical Polymer's (HKG:1066) Returns On Capital Are Heading Higher

Mar 17
Shandong Weigao Group Medical Polymer's (HKG:1066) Returns On Capital Are Heading Higher

Is There An Opportunity With Shandong Weigao Group Medical Polymer Company Limited's (HKG:1066) 42% Undervaluation?

Jan 28
Is There An Opportunity With Shandong Weigao Group Medical Polymer Company Limited's (HKG:1066) 42% Undervaluation?

Does Shandong Weigao Group Medical Polymer (HKG:1066) Deserve A Spot On Your Watchlist?

Jan 13
Does Shandong Weigao Group Medical Polymer (HKG:1066) Deserve A Spot On Your Watchlist?

Returns Are Gaining Momentum At Shandong Weigao Group Medical Polymer (HKG:1066)

Dec 17
Returns Are Gaining Momentum At Shandong Weigao Group Medical Polymer (HKG:1066)

Shandong Weigao Group Medical Polymer (HKG:1066) Seems To Use Debt Rather Sparingly

Dec 05
Shandong Weigao Group Medical Polymer (HKG:1066) Seems To Use Debt Rather Sparingly

An Intrinsic Calculation For Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) Suggests It's 32% Undervalued

Oct 18
An Intrinsic Calculation For Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) Suggests It's 32% Undervalued

Prognoser för vinst- och omsättningstillväxt

SEHK:1066 - Analytikernas framtida uppskattningar och tidigare finansiella data (CNY Millions )
DatumIntäkterIntäkterFritt kassaflödeKassaflöde från rörelsenGenomsnittligt Antal analytiker
12/31/202615,3392,4452,9153,8757
12/31/202514,4832,2812,6182,6238
12/31/202413,6262,1142,0863,1039
6/30/202412,9671,9122,0182,704N/A
3/31/202413,0981,9572,0662,751N/A
12/31/202313,2292,0022,1132,799N/A
9/30/202313,3982,2211,6392,539N/A
6/30/202313,5662,4401,1662,280N/A
3/31/202313,6572,6021,1732,287N/A
12/31/202213,7472,7641,1812,295N/A
9/30/202213,9032,6761,4332,573N/A
6/30/202214,0582,5891,6852,852N/A
3/31/202213,6332,4321,8032,969N/A
12/31/202113,2092,2761,9203,087N/A
9/30/202112,9232,2882,0213,088N/A
6/30/202112,6362,3002,1213,089N/A
3/31/202112,1292,1941,9712,938N/A
12/31/202011,6222,0871,8212,788N/A
9/30/202011,1391,9981,5572,533N/A
6/30/202010,6561,9091,2922,277N/A
3/31/202010,5201,8791,3152,300N/A
12/31/201910,3841,8501,3372,322N/A
9/30/20199,9931,8051,4562,347N/A
6/30/20199,6021,7601,5752,371N/A
3/31/20199,2051,6161,5002,295N/A
12/31/20188,8091,4731,4242,219N/A
6/30/20187,4651,2553831,812N/A
3/31/20186,8791,255N/A1,539N/A
12/31/20176,2931,255N/A1,266N/A
6/30/20175,4021,297N/A1,233N/A
3/31/20175,5111,165N/A1,143N/A
12/31/20165,6201,033N/A1,053N/A
9/30/20166,4841,010N/A1,042N/A
6/30/20166,237914N/A1,030N/A
3/31/20166,0781,013N/A1,041N/A
12/31/20155,9191,113N/A1,053N/A
9/30/20155,8781,237N/AN/AN/A
6/30/20155,6101,196N/A622N/A
3/31/20155,5481,161N/AN/AN/A
12/31/20145,2781,085N/A711N/A
9/30/20145,011307N/AN/AN/A
6/30/20144,996431N/A794N/A
3/31/20144,769376N/AN/AN/A

Analytiker Framtid Tillväxt Prognoser

Intäkter kontra sparande: 1066 s prognostiserade vinsttillväxt ( 9.3% per år) är över sparkvoten ( 2.4% ).

Resultat vs marknad: 1066 s intäkter ( 9.3% per år) förväntas växa långsammare än marknaden för Hong Kong ( 11.7% per år).

Höga tillväxtresultat: 1066 s intäkter förväntas växa, men inte avsevärt.

Intäkt vs marknad: 1066 s intäkter ( 6.6% per år) förväntas växa långsammare än marknaden för Hong Kong ( 7.8% per år).

Hög tillväxtintäkter: 1066 s intäkter ( 6.6% per år) förväntas växa långsammare än 20% per år.

Tillväxtprognoser för vinst per aktie

Framtida avkastning på eget kapital

Framtida ROE: 1066 s avkastning på eget kapital förväntas bli låg om 3 år ( 9.1 %).

Upptäck tillväxtföretag

7D

1Y

7D

1Y

7D

1Y

Företagsanalys och finansiella data Status

UppgifterSenast uppdaterad (UTC-tid)
Analys av företag2025/03/06 09:24
Aktiekurs vid dagens slut2025/03/06 00:00
Intäkter2024/06/30
Årlig intjäning2023/12/31

Datakällor

Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.

PaketUppgifterTidsramExempel US-källa
Företagets finansiella ställning10 år
  • Resultaträkning
  • Kassaflödesanalys
  • Balansräkning
Analytikernas konsensusuppskattningar+3 år
  • Prognos för finansiella poster
  • Analytikernas prismål
Marknadspriser30 år
  • Aktiekurser
  • Utdelningar, splittar och åtgärder
Ägarskap10 år
  • Största aktieägare
  • Insiderhandel
Förvaltning10 år
  • Ledningsgrupp
  • Styrelse och verkställande direktörer
Viktiga utvecklingstendenser10 år
  • Företagsmeddelanden

* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.

Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.

Analysmodell och snöflinga

Detaljer om den analysmodell som används för att generera denna rapport finns på vår Github-sida, vi har också guider om hur man använder våra rapporter och tutorials på Youtube.

Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.

Industri- och sektormått

Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.

Källor för analytiker

Shandong Weigao Group Medical Polymer Company Limited bevakas av 36 analytiker. 8 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.

AnalytikerInstitution
Jason MannBarclays
Derrick SunBNP Paribas Securities (Asia)
Jessica LiBofA Global Research